Semaglutide dosage in clinical trials

Doses in published trials

Arms as registered

Verbatim arm text from ClinicalTrials.gov, for the 40 highest-phase and most recent of 287 matching studies. Only arms naming Semaglutide and a dose are shown.

1. NCT07770282 · Phase 3 · Not yet recruiting · n=600

   Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome

   • Semaglutide — Drug: Semaglutide - oral tablet 3 mg once daily in the morning (titrated up from a low starting dose over 5 days), added to ongoing second-generation antipsychotic (TAU), for 24 weeks.

2. NCT07743983 · Phase 3 · Recruiting · n=372

   A Study of BGM0504 in Early T2DM With Obesity

   • Semaglutide Injection 1.0 mg

3. NCT07653477 · Phase 3 · Recruiting · n=956

   Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)

   • Semaglutide Injection 1mg group — S.C. once weekly

4. NCT06913023 · Phase 2/Phase 3 · Not yet recruiting · n=37

   Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

   • Semaglutide — Patients will be up-titrated as tolerated starting at 0.25 mg subcutaneous semaglutide once weekly for 4 weeks, followed by 0.5 mg, 1.0 mg, and 1.7 mg semaglutide for 4 weeks each, and then 2.4 mg subcutaneous semaglutide once weekly for 8 weeks. Semaglutide can be down-titrated by the investigator to lower doses or up-titrated at slower rates if not tolerated by the participant.

5. NCT06934655 · Phase 3 · Recruiting · n=150

   Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth

   • Early reinitiation — Early Reinitiation of semaglutide at 2 weeks after bariatric surgery per standard titration starting at 0.25 mg weekly and titrating to 2.4 mg weekly

6. NCT07218354 · Phase 3 · Recruiting · n=622

   Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

   • Semaglutide — Weekly subcutaneous injections of semaglutide up to 2.4 milligram (mg)/week or maximum tolerated dose. Initial dosing starting at 0.25 for weeks 1-4. Further titration up to 2.4 mg weekly starting at week 5.

7. NCT07581145 · Phase 3 · Recruiting · n=52

   Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients

   • semaglutide — Ozempic® (semaglutide), which comes in prefilled pens, is approved for treatment of adults with insufficiently controlled type 2 diabetes mellitus. This group is treated with semaglutide 1 mg once weekly, with the usual starting dose of injection 0.25 mg semaglutide subcutaneously once weekly (OW). After four weeks the dose will be increased to 0.5 mg OW, and after another four weeks, the dose will be increased to 1.0 mg OW, depending on side effects. Novo Nordisk A/S will deliver the IP and will do so in a way that enables double blind treatment. The strength of the active IP used in this study is semaglutide 1.34 mg/ml.

8. NCT07295223 · Phase 3 · Recruiting · n=44

   Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

   • Semaglutide — Semaglutide 3 mg, gradually increasing to 14 mg every 24 hours over 24 weeks.

9. NCT07297589 · Phase 3 · Recruiting · n=136

   Epicardial Cardiac Fat-CT (EPIC-CT)

   • Semaglutide — Semaglutide 3 mg, gradually increasing to 14 mg every 24 hours

10. NCT07834398 · Phase 3 · Completed · n=150

    Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes

    • Semaglutide Group — Includes 50 non-diabetic obese participants receiving semaglutide 2.4 mg subcutaneous once weekly for 24 weeks

11. NCT06909006 · Phase 3 · Not yet recruiting · n=122

    Semaglutide Treatment in Type 1 Diabetes

    • Semaglutide — Subcutaneous injection through injector pen with the active comparator Semaglutide once a week in monthly increasing doses as given: 0.25mg - 0.5mg - 1.0mg - 1.7mg - 2.4mg

12. NCT07150975 · Phase 3 · Recruiting · n=420

    Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

    • Semaglutide(Wegovy® )2.4 mg

13. NCT07139548 · Phase 3 · Not yet recruiting · n=600

    A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

    • 1 mg Semaglutide — 1 mg semaglutide administered SC once a week.

14. NCT07046273 · Phase 3 · Not yet recruiting · n=496

    Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

    • Ozempic® — The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.

15. NCT07064486 · Phase 3 · Active, not recruiting · n=152

    A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

    • 1 mg Semaglutide — 1 mg semaglutide administered SC once a week

16. NCT07030621 · Phase 3 · Not yet recruiting · n=436

    Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

    • semaglutide group — The patients will receive a subcutaneous injection of 0.5 mg semaglutide into the abdomen during endovascular thrombectomy

17. NCT06946628 · Phase 3 · Not yet recruiting · n=296

    New Triple Therapy in Newly Diagnosed Type 2 Diabetes

    • Group A (triple combination therapy group) — semaglutide, empagliflozin, and pioglitazone treatment. 1) Initiate with Semaglutide 0.25 mg once weekly (qw) + Empagliflozin 10 mg once daily (qd) + Pioglitazone 15 mg once daily (qd); 2) After 1 month, if blood glucose is not controlled, adjust to Semaglutide 0.5 mg qw + Empagliflozin 20 mg qd + Pioglitazone 30 mg qd. If Semaglutide is well-tolerated, increase to 1 mg qw after 1 week; 3)If blood glucose remains uncontrolled after 1 month, add basal insulin therapy.
    • Group B (standard therapy group) — metformin-based treatment is recommended when not contraindicated. 1).Initiate with Metformin monotherapy, titrate to the target dose of 1000 mg twice daily (bid) within 1 month or to the maximum tolerated dose (if Metformin is not tolerated, switch to Linagliptin 5 mg qd); 2) After 1 month, if blood glucose is not controlled, add a second antidiabetic drug, Empagliflozin 20 mg qd; 3) After another month, if blood glucose remains uncontrolled, add Semaglutide 0.25 mg qw, then increase to 0.5 mg qw after 1 month. If well-tolerated, increase to 1.0 mg qw after 1 week; 4) If blood glucose remains uncontrolled after 1 month, add basal insulin therapy.

18. NCT06499857 · Phase 3 · Recruiting · n=200

    Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

    • Semaglutide — Participants will have a 2 in 3 chance of receiving semaglutide (2.4 mg).

19. NCT06894784 · Phase 3 · Recruiting · n=36

    A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

    • Semaglutide, Ozempic® (at maximum tolerated dose) + Automated Insulin Delivery system — Semaglutide is a Glucagon-Like Peptide 1 Receptor Agonist. It stimulates GLP1 in the body, which allows for increased satiety, reduced glucagon levels, delayed gastric emptying, and in some, increased insulin secretion. It is a once per week subcutaneous injection. Participants will self-administer the colourless solution subcutaneously in the abdomen, thighs, or upper arms once weekly per the dosing schedule below. Weeks 1-4 : 0.25 mg (0.19 mL) Weeks 5-8 : 0.50 mg (0.38 mL) Weeks 9-12 : 1.0 mg (0.74 mL) Weeks 13-22 : 1.0 mg (0.74 mL) To match the recommendation from the product monograph and to ensure a steady state is reached before initiating the evaluation period, study drugs will be titrated for 12 weeks.

20. NCT06937060 · Phase 3 · Recruiting · n=14

    Effect of Semaglutide in Patients With Psoriasis and Obesity

    • Active (alternative intervention) — Semaglutide is act as an adjunct to a reduced calorie diet and increase physical activity for chronic weight management in obesity or overweighted adult. Initiate Semaglutide with a dosage of 0.25 mg injected subcutaneously once-weekly, from week 1 to week 24, i.e. 24 dosage of Semaglutide in total.

21. NCT06788626 · Phase 3 · Not yet recruiting · n=390

    Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

    • semaglutide — Participants will receive 0.5mg semaglutide injection before (Day 0) and 1 week (Day 7) after EVT. Additionally, they will receive antiplatelet drugs, anticoagulation or combinations of these treatment modality according to national and institutional guidelines.

22. NCT06716216 · Phase 3 · Active, not recruiting · n=537

    A Study of BGM0504 in Participants With Type 2 Diabetes

    • Active Comparator: 1 mg Semaglutide 1 mg semaglutide administered SC once a week — Drug: Semaglutide Administered SC

23. NCT06896981 · Phase 2/Phase 3 · Completed · n=31

    Semaglutide in Women With Polycystic Ovary Syndrome and Obesity

    • Metformin and semaglutide — Immediately release metformin 500 mg bd for 12 weeks and Inj Semaglutide 0.5 mg once weekly for 12 weeks

24. NCT07092618 · Phase 2/Phase 3 · Recruiting · n=150

    Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

    • Metformin + LDN — Month 1: 500mg/d MET, reduce Wegovy (or equivalent) to 1.7mg/wk or Ozempic (or equivalent) to 1.0mg/wk, add LDN 1.5mg b.i.d. Month 2: Increase MET to 1000mg/d, reduce Wegovy (or equivalent) to 1.0mg/wk or Ozempic (or equivalent) to 0.5mg/wk, increase LDN to 3mg b.i.d. Month 3: Increase MET to 1500mg/d, reduce Wegovy (or equivalent) to 0.5mg/wk or Ozempic (or equivalent) to 0.25mg/wk, increase LDN to 4.5mg b.i.d. Months 4-12: increase MET to 2000mg/d, stop Wegovy (or equivalent) or Ozempic (or equivalent) entirely, continue LDN 4.5mg b.i.d.
    • Metformin — Month 1: 500mg/d MET, reduce Wegovy (or equivalent) to 1.7mg/wk or Ozempic (or equivalent) to 1.0mg/wk Month 2: Increase MET to 1000mg/d, reduce Wegovy (or equivalent) to 1.0mg/wk or Ozempic (or equivalent) to 0.5mg/wk Month 3: Increase MET to 1500mg/d, reduce Wegovy (or equivalent) to 0.5mg/wk or Ozempic (or equivalent) to 0.25mg/wk Months 4-12: increase MET to 2000mg/d, stop Wegovy (or equivalent) or Ozempic (or equivalent) entirely
    • Metformin + Rapamycin — Month 1: 500mg/d MET, reduce Wegovy (or equivalent) to 1.7mg/wk or Ozempic (or equivalent) to 1.0mg/wk, add 1mg/wk rapamycin Month 2: Increase MET to 1000mg/d, reduce Wegovy (or equivalent) to 1.0mg/wk or Ozempic (or equivalent) to 0.5mg/wk, increase rapamycin to 2mg/wk Month 3: Increase MET to 1500mg/d, reduce Wegovy (or equivalent) to 0.5mg/wk or Ozempic (or equivalent) to 0.25mg/wk, increase rapamycin to 4mg/wk Months 4-12: increase MET to 2000mg/d, stop Wegovy (or equivalent) or Ozempic (or equivalent) entirely, increase rapamycin to 6mg/wk
    • Placebo (Vitamin C) — Month 1: 250mg/d Vitamin C, reduce Wegovy (or equivalent) to 1.7mg/wk or Ozempic (or equivalent) to 1.0mg/wk Month 2: Increase Vitamin C to 500mg/d, reduce Wegovy (or equivalent) to 1.0mg/wk or Ozempic (or equivalent) to 0.5mg/wk Month 3: Increase Vitamin C to 750mg/d, reduce Wegovy (or equivalent) to 0.5mg/wk or Ozempic (or equivalent) to 0.25mg/wk Months 4-12: increase Vitamin C to 1000mg/d, stop Wegovy (or equivalent) or Ozempic (or equivalent) entirely

25. NCT06616961 · Phase 3 · Not yet recruiting · n=480

    Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus

    • Semaglutide — This study features a single treatment arm where participants receive semaglutide (Fitaro) for weight management. Administered subcutaneously once weekly, the treatment begins at 0.25 mg and escalates to a maximum of 2.4 mg over 16 weeks based on individual response and tolerance. Participants include overweight or obese adults aged 18 and older, with or without Type 2 Diabetes Mellitus (T2DM). The primary focus is to assess the efficacy and safety of semaglutide in achieving significant weight loss, while also evaluating its impact on metabolic parameters like body mass index (BMI), waist circumference, blood glucose levels, and overall quality of life. Alongside medication, participants will receive lifestyle counseling to encourage dietary adjustments and increased physical activity. Regular follow-up assessments will be conducted to monitor weight loss progress, metabolic health, and any treatment-related adverse events throughout the study duration.

26. NCT06649344 · Phase 3 · Completed · n=884

    A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

    • Treatment group C — Semaglutide-1mg

27. NCT06633783 · Phase 3 · Not yet recruiting · n=370

    A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

    • Semaglutide injection — Semaglutide：0.25 mg、0.5 mg、1.0mg、1.7mg、2.4mg
    • Wegovy® — Wegovy®：0.25 mg、0.5 mg、1.0mg、1.7mg、2.4mg

28. NCT06058585 · Phase 3 · Recruiting · n=2,000

    The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

    • Semaglutide — Semaglutide 1.0 mg or 2.4 mg pen injector

29. NCT06082063 · Phase 3 · Recruiting · n=2,000

    Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

    • Multifactorial intervention group — The multifactorial intervention will be determined by the risk profile and risk markers of each individual and the participants will be allocated to Semaglutide, sotagliflozin or finerenone. The intervention will also comprise more ambitious treatment targets for blood pressure and lipid levels. In addition, all participants will take aspirin 75 mg OD.

30. NCT06361823 · Phase 3 · Unknown status · n=74

    Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment

    • Semaglutide — Expanding on the usual treatment regimen, Semaglutide is administered through a subcutaneous injection once weekly over a period of 3 months. Initially, the dose is 0.25 mg for the first month, then increased to 0.5 mg for patients who could tolerate it in the second month, and finally raised to 1.0 mg for patients who still tolerated it in the third month.

31. NCT06423599 · Phase 2/Phase 3 · Recruiting · n=100

    Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure

    • Semaglutide intervention group — Dose-escalation of semaglutide will take place during the first 16 weeks after randomisation (week 0). Patients will start at the 0.25 mg once-weekly dose and follow dose-escalation schedule (0.25, 0.5, 1.0, 1.7 and 2.4 mg). For all subjects we aim at reaching the recommended target dose of 2.4 mg semaglutide once weekly for the rest of the period of total 52 weeks.

32. NCT06339086 · Phase 3 · Unknown status · n=478

    Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes

    • Semaglutide Injection — Semaglutide 0.25mg、0.5mg、1.0mg Metformin ≥ 1500mg/day (or maximum tolerated dose ≥ 1000mg/day) and ≤2000mg/day
    • Ozempic® — Ozempic® 0.25mg、0.5mg、1.0mg Metformin ≥ 1500mg/day (or maximum tolerated dose ≥ 1000mg/day) and ≤2000mg/day.

33. NCT06161844 · Phase 3 · Completed · n=506

    Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

    • Semaglutide injection (HD1916) — Up to 1.0 mg semaglutide (HD1916) Metformin ≥ 1500 mg/day
    • Ozempic® — Up to 1.0 mg semaglutide (Ozempic®) Metformin ≥ 1500 mg/day

34. NCT06083675 · Phase 3 · Withdrawn

    Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

    • Semaglutide 25 mg — Participants will receive 25 mg oral semaglutide once daily in maintenance period after dose escalation period.
    • Semaglutide 50 mg — Participants will receive 50 mg oral semaglutide once daily in maintenance period after dose escalation period.

35. NCT06131437 · Phase 3 · Completed · n=809

    A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

    • CagriSema 2.4 mg/2.4 mg — Participants will receive 2.4 mg cagrilintide and 2.4 mg semaglutide subcutaneously once-weekly (dose escalation period of 16 weeks) for up to 84 weeks.

36. NCT05819853 · Phase 3 · Recruiting · n=80

    Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

    • Untreated PCOS — Participants with PCOS who are not on metformin or hormonal therapy, will receive 10-months of semaglutide intervention. Participants will get either semaglutide as either: Wegovy: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg 4-weeks, and 1.7mg for the remainder of the study. or Ozempic: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg 4-weeks, and Wegovy for 1.7mg for the remainder of the study.
    • PCOS on Metformin — Participants with PCOS who are currently on metformin and still not having regular menses, will receive 10-months of semaglutide intervention. Participants in this arm will continue to take their metformin throughout the trial. Participants will get either semaglutide as either: Wegovy: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg 4-weeks, and 1.7mg for the remainder of the study. or Ozempic: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg 4-weeks, and Wegovy for 1.7mg for the remainder of the study.

37. NCT05788965 · Phase 2/Phase 3 · Completed · n=8

    Semaglutide in CFRD

    • Single Arm — Semaglutide 1 mg once weekly subcutaneous injection

38. NCT06045221 · Phase 3 · Completed · n=1,698

    A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

    • 7 mg Semaglutide — Participants initiated treatment with a 3 mg once-daily oral dose of semaglutide and increased the dose every 4 weeks until the targeted dose of 7 mg once-daily was reached, after which this dose was to be continued for the remainder of the 52-week treatment period.
    • 14 mg Semaglutide — Participants initiated treatment with a 3 mg once-daily oral dose of semaglutide and increased the dose every 4 weeks until the targeted dose of 14 mg once-daily was reached, after which this dose was to be continued for the remainder of the 52-week treatment period.

39. NCT05813912 · Phase 3 · Completed · n=148

    A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes

    • Insulin Icodec + Semaglutide — Participants will receive insulin icodec once weekly for 26 weeks in run-in period to ensure the dose optimization. Thereafter, participants meeting intensification criteria will proceed to the 26-week treatment period to receive once weekly semaglutide subcutaneously starting from 0.25 milligrams (mg) and dose increased up to 1 mg along with 700 units per milliliter (U/mL) insulin icodec therapy. There are no maximum or minimum insulin doses.

40. NCT06041217 · Phase 3 · Completed · n=242

    A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

    • Semaglutide 2.4 milligram (mg) — Participants will receive once-weekly subcutaneous (s.c) injection of semaglutide for 44 weeks.